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ABSTRACT 
 
Aim 
To develop a systems based approach for community nurse requests for home 
medicines review (HMR) referral, measure the degree of uptake of these requests for 
HMR, and identify barriers to uptake of HMR referrals as part of the developed 
system. 
Method 
An area of southern Brisbane suburbs was selected encompassing three Divisions of 
General Practice and three Blue Care nursing centres.  Stakeholder meetings 
involving interested parties were convened to determine process issues.  Patients 
identified as having potential medication related problems were recruited by Blue 
Care nurses and tracked through the normal HMR process.  Focus groups were 
conducted with each professional group involved in the project (pharmacists, general 
practitioners (GPs) and Blue Care nurses) to discuss and identify barriers in the 
project and also general barriers to HMR uptake in the community. 
Results 
Five requests for HMR referral were completed and sent to the GP during the seven 
months of this study.  Of these, three (60%) HMR referrals were generated by the GP 
and sent to the pharmacy.  One referral was withdrawn by the GP and two referrals 
(40%) resulted in a completed HMR.  Two focus groups each were conducted with 
Blue Care nurses and GPs and one with pharmacists.   
Conclusion 
The HMR program remains in its infancy with much untapped potential.  Patient and 
health professional acceptance of the program remain key barriers to its continued 
uptake and success. 
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INTRODUCTION 
 
Health budgets worldwide are under constant pressure yet continue to expand at an 
alarming rate.  In this climate cost savings are continually being sought.  Iatrogenesis 
is an area that can be easily targeted to reduce health costs while at the same time 
providing patient benefits through reduced error and medical visits/hospitalisations. 
The Australian Council for Safety and Quality in Healthcare (1), the US Institute of 
Medicine (2) and the UK Department of Health (3) have identified the potential 
financial and patient benefit savings which can be realised if a systematic approach is 
taken to errors in healthcare. 
 
While governments and other organisations that fund the healthcare system 
predominantly concentrate on the fiscal aspect of any savings, the patients, or 
consumers, of the healthcare system are the ultimate beneficiaries of error reduction.  
Improved patient safety will flow through to reduced hospital stays and less frequent 
repeat visits to hospitals and other healthcare facilities.  This, in turn, will further 
drive expenditure down thereby allowing a greater capacity in the healthcare system.  
However, “siloism” has long been a problem in government circles, as each program 
appears only to be interested in its own outcomes.  This narrow focus inhibits cross-
links between programs to improve services and therefore producing the best 
outcomes for both the funder (government) and the consumer (patient). 
 
A study investigating the incidence and severity of adverse events after hospital 
discharge by telephone survey of 400 recently discharged patients found an adverse 
event occurred in 76 (19%) of patients (4).  Of these adverse events, 50 (66%) were 
due to an adverse drug event and a panel of internal medicine specialists classified 31 
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(62%) as either preventable or ameliorable.  “Ameliorable” was used to describe 
events whose severity could have been reduced if different actions or procedures had 
been taken or followed.  Poor communication was found to be the main causal 
contributor to adverse events, both between the hospital and primary health care 
providers and with the patient themselves.  Four system issues were identified as 
requiring improvement including patient education about drug and other therapies and 
monitoring of drug and other therapies after discharge.  One recommendation to 
reduce adverse drug events was telephone contact within 5 days of discharge with a 
clinical pharmacist. 
 
Medicines are a part of daily life for many Australians.  People aged over 65 years 
comprise 13% of the Australian population (5), yet consume 35% of the health 
expenditure (6).  When broken down into its component costs, this comprises 35% of 
acute hospital services, 31% of pharmaceutical services and 24% of medical services.  
It is considered that lifestyle modification could prevent or postpone approximately 
80% of the health problems associated with ageing in Australia, especially when 
cardiovascular diseases and cancers account for over 60% of the disease burden in 
those aged over 65 years (6). 
 
The elderly are more likely to use medication and also more likely to be exposed to 
polypharmacy.  As people age, they also become more sensitive to medications for a 
range of reasons: 
 Reduced renal function; 
 Decreased lean muscle mass; 
 Increased body fat; 
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 Reduced total body water; 
 Altered receptor sensitivity; and 
 Increased sensitivity to drugs acting on the CNS (7). 
Consequently, this population is more likely to experience an adverse medicine event.   
 
A range of initiatives were sought by the Australian Government to reduce the ageing 
burden on the healthcare system while at the same time promoting preventative 
strategies to promote lifestyle changes and optimise care.   
 
Medication review 
 
Medication problems in Australia were estimated in 1999 to result in at least 80,000 
hospital admissions with an associated cost of approximately $350 million (8).  Other 
studies have shown between 1.7 and 16.8% of hospital admissions to be due to drug 
related causes (9-15), and up to 24% when specifically investigating an elderly 
population (16).  One study further categorised adverse drug reactions (ADR) at 
admission and found that while 7.2% of patients were admitted due to an ADR, 21.4% 
of patients admitted actually had an ADR (15).   A recent prospective six-month study 
of 18,820 hospital admissions in England showed adverse drug reactions were 
responsible for 1225 (6.5%) of the admissions.  Of these, 203 (16.6%) were due to 
drug interactions and 28 (2.3%) were fatal.  The authors determined that 72% of all 
the admissions related to adverse drug reactions were avoidable and may be reduced 
by regular medication review and involving pharmacists in assessing prescribing 
behaviour.  They also acknowledged that the true community incidence of adverse 
drug reactions may be at least double that shown in the study when those reactions not 
resulting in a hospital admission are taken into account (17). 
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Roberts et al secured funding to survey the medications used in 15 nursing homes in 
southeast Queensland and northern New South Wales involving 998 residents.  The 
mean number of medications prescribed per patient was 6.6 and the mean number 
administered was 4.8.  They also found that as the degree of incapacity of the resident 
decreased, so too did the use of both benzodiazepines and psycholeptics (18). 
 
On the basis of the results uncovered in the medication survey, Roberts et al 
conducted a further study in the same geographical area, involving 52 nursing homes 
with 3230 residents.  This was a randomised controlled clinical trial with clinical 
pharmacy services (medication review, nurse education and relationship building) as 
the intervention.  The study demonstrated that clinical pharmacy intervention in 
residential aged care facilities could produce a trend towards  reduction in total drug 
use.   A trend towards  increased survival of residential aged care facility residents 
was also found.  A significant cost saving in medication alone of $64 per resident was 
found, or $16 per resident net saving after allowing for the cost of the clinical 
pharmacy service (19).  Funding commenced for medication reviews by accredited 
pharmacists of medications used by nursing home and hostel residents in 1997 (20).   
 
Studies were commissioned by the Commonwealth Department of Health in 
conjunction with the Pharmacy Guild of Australia (Guild) to explore various models 
to extend the nursing home medication review program to the home situation.  Four 
studies were funded, which explored similar models, but with subtle differences so 
that a range of potential models were evaluated (21-24).  The final Home Medicines 
11 
Review model was developed through a consultative process involving a 
multidisciplinary steering committee (25). 
 
Hospital discharge procedures in Australia do not link well with community service 
providers to provide continuity of care and it has been shown that elderly patients who 
are discharged from hospital have a high risk of readmission (4).  An Australian study 
that investigated the impact of medication review 5 days post discharge for elderly 
patients discharged from Royal Hobart Hospital found the number of unplanned 
readmissions was significantly reduced (26).  Community nurses care for many 
patients after discharge from hospital, and therefore can provide a valuable link in the 
health care continuum from hospital to community.  Although medication problems 
are only one factor involved in hospital readmission, Forster et al (4) found adverse 
medication events to be responsible for 66% of hospital readmissions and Naunton et 
al (26) demonstrated the value of medication review. 
 
The Australian Commonwealth Government introduced home Medicine Reviews 
(HMR) in October 2001 (27).   During the first three years of the program to 31 
October 2004, 59,397 HMR’s had been conducted costing some $8,315,580 (28).  
While this appears to be a good uptake of the program, further analysis shows a poor 
uptake with 12.1 HMR’s per pharmacy since the program’s inception, or 4.0 HMR 
per pharmacy per year when averaged across the nation’s 4925 pharmacies. 
 
The objectives of the HMR program are to: 
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 “achieve safe, effective, and appropriate use of medications by detecting and 
addressing medication-related problem/s that interfere with desired patient 
outcomes;  
 improve the patient's quality of life and health outcomes using a best practice 
approach, that involves a collaborative effort between the general practitioner, 
pharmacist, other relevant health professionals and the patient (and where 
appropriate, their carer);  
 improve the patient's, and health professionals' knowledge and understanding 
about medications; and  
 facilitate cooperative working relationships between members of the health 
care team, in the interests of patient health and well-being.” (29)  
 
There are four basic stages to a HMR: 
1. “The identification of patients who may benefit from the review, for example 
patients: 
 on multiple medications;  
 who have recently been discharged from hospital; 
 with recent and significant changes to their medications; or 
 who are attending a number of different GPs and specialists.  
While a review can only be instigated by a GP, the suggestion that a patient 
might benefit from a review can also come from other health professionals or 
the patient themself. The patient consults with their GP, allowing the GP to 
assess whether a HMR is clinically necessary to ensure quality use of 
medicines or address the patient's needs. The patient chooses the community 
pharmacy they would prefer to coordinate the review.  
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2. The community pharmacy coordinates the review, letting the GP know the 
arrangements for the review and the contact details of the accredited 
pharmacist. The accredited or community pharmacist arranges a suitable time 
to interview the patient, preferably in the patient's own home. The review may 
be carried out at another location of the patient’s choice; however his or her 
own home is preferable. The interviewing pharmacist conducts the review 
including an examination of all the patient's medications and related devices. 
This pharmacist also identifies any issues the patient may have with their 
medications, for example, compliance, storage and administration techniques. 
The accredited pharmacist conducts a clinical assessment of the information 
gathered during the patient interview and writes a report that includes their 
findings and recommendations.  
 
3. The report is then be discussed with the GP, either face-to-face or by phone, 
who decides on a course of action.  
 
4. The GP arranges a consultation with the patient to discuss the results and 
develop a written medication plan for agreement with the patient.” (30) 
 
A randomised controlled trial conducted in America using a similar model to the 
Australian HMR model in community dwelling geriatric patients was conducted in 
1993-95, but only recently published (31).  The findings showed a significant dollar 
saving in the intervention group, but that not all consultant pharmacist 
recommendations for medication cessation were followed.  If all recommendations 
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had been followed, the savings would have been four-fold those actually recorded.  In 
terms of behaviour change by patients, this study found that patients were unwilling to 
discontinue psychoactive drugs and generally only accepted advice about medication 
changes one third of the time.  This is more alarming when the patients were informed 
that their primary care doctor agreed to the changes!  The Australian model where the 
doctor discusses the HMR findings directly with the patient could improve outcomes 
in this area, but requires evaluation of the current HMR model. 
 
To date, the Australian HMR model has not been evaluated, however the Guild has 
issued a request for tender to evaluate the HMR program.  This evaluation is due for 
completion in April 2005 with a final report to be submitted to the Guild by June 2005 
(32). 
 
Nurse triage 
Nurses are widely involved in a range of triage roles throughout the world.  The first 
point of contact for the majority of non-ambulance arrivals at emergency departments 
is the triage nurse.   Nurses are trained to care for patients and can also adopt a 
gatekeeping role for entry into other medical services.  This has been shown to be 
effective in providing mental health services to people in their own homes in rural 
communities by District Nurses in the UK (33).   
 
Nurse involvement in triage and gatekeeping appears to be a burgeoning area.  The 
impact of including a specialist nurses in emergency rooms to increase care provided 
in specialist areas such as mental health or eye problems have been investigated with 
good results (34-36).  Nurse involvement in a Canadian specialist neurology 
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outpatient clinic and even as gatekeepers for GP services in the UK has also been 
shown to improve patient contact while filtering out the cases that do not require 
referral on to the doctor (37, 38).  The use of nurses in these roles has reduced costs to 
the various services over employing the same number of medical specialists, but it is 
conversely argued that the nurse is providing a triage service – treating those patients 
he/she can and referring the other patients, as appropriate, to specialist medical care.  
Using this model, medical services can be used more efficiently (37).   
 
The other consideration apart from economics is patient care.  Fremantle hospital in 
Perth successfully trialled and then implemented a model for inclusion of a mental 
health triage and consultancy service in their busy emergency room. This program 
showed improved patient outcomes, and reduced the number of patients, with mental 
health problems who left the Emergency Department without being seen (35, 36).  
These results, in conjunction with the District Nurse results in the UK (33) show that 
both hospital and community outcomes can be improved through the involvement of 
appropriately trained nurses in a triage/gatekeeper role.  These outcomes could be 
extrapolated to the involvement of community nurses identifying medication 
problems in their clients in their own homes. 
 
The new push in  primary health care is towards utilising nurse practitioners as “the 
face” of primary care who then refer on to the appropriate service provider including 
general practitioners.  The new horizon of nurse led care is a model causing some 
angst in medical circles.  These frontiers of medical practice are being explored in 
both the UK and USA from a financial and patient care viewpoint.  “Nurse-led care” 
is the phrase coined in the UK, whereas “collaborative care” is the less 
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confrontational name used in the USA (39, 40).  Whichever label is applied to the 
model of care, there is greater involvement of nurses in the primary assessment of 
patients and referral on to appropriate services – triage.  Although appropriate training 
for nurses is identified as a current barrier to this care model, it can be overcome by 
reviewing educational curricula to encompass the new role.  In the same manner, 
training can expand current nursing roles to identify appropriate patients for HMR and 
refer on to their general practitioner for assessment and HMR referral as appropriate. 
 
Systems development 
 The systems implementation literature, especially in the healthcare arena, tends to 
focus on implementation of information systems.  This is the “new frontier” in 
healthcare and its implementation is an ideal time to review existing processes 
through the systemisation process.  Adding information technology solutions to a 
flawed system will not improve it (41), but only produce a more cumbersome result.  
Therefore much of the information system implementation is an exploration onto the 
deeper system issues in healthcare delivery (42).  The primary flaw in a range of these 
information system implementations was a lack of analysis of the underlying existing 
healthcare delivery system.  
 
Developing a new system is never an easy task.  Careful planning of the system in 
addition to, or often as part of consultation with stakeholders to build a consensus of 
the intended direction are important elements.  Change is often difficult for people, 
but maintaining information flow throughout the implementation and adopting a “user 
view” of the system can help prevent unnecessary angst (43).   
 
17 
User involvement during all phases of system design, development, implementation 
and evaluation is essential to the success of a system.  Failure to include the user 
viewpoint in any of these phases will result in a system doomed to failure.  This is 
often not caused through a deliberate ploy of users, but rather a system that may be 
technically perfect, but practically flawed (41, 44).  Systems that have the best 
practical applicability and also management appeal are “simple, frugal and focussed” 
(45), thus providing ease of implementation and deliverable outcomes.  People, 
however, are not machines and therefore systems involving people and organisations 
must take into account the complex patterns of cause and effect.  While the 
intervention may only involve a simplistic chain of events, the organisation or people 
involved in delivering that event(s) are not simplistic.  Consequently any change may 
require redesign of interventions due to time delays and unintended consequences 
(46).   
 
Chen et al (47) described the use of a model drawing on two theoretical models for 
developing their framework which was used in one of the HMR implementation trial 
studies (21). This model draws on the Diffusion of Innovations model and the 
Linkage model.  This framework provides a pathway for development and 
implementation of new processes in a healthcare arena with a sound basis in the social 
sciences.  Chen’s model defines a stepwise series of main events and provides a 
system for implementation of new ideas or processes in the healthcare arena (Figure 
1). 
Implementing a procedural change within one specialty area, for example a nursing 
care documentation process developed by nurses is a less complex exercise.  A 
process such as this can be designed by nurses with reference to the published 
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2. Steering committee 
convened 
3. Disseminate information  
to practitioners 
4. Training programme  
for practitioners 
5. Provision of new service by 
practitioners 
1. Initial meeting to gauge  
support for project 
literature and best practice and when implemented produce results (45).  However, 
when designing and implementing a multidisciplinary process involving a range of 
interest groups (often with their own agendas), the consultative approach is invaluable 
to obtain engagement from each interest group.  This provides a “champion” in each 
sector represented to support and promote the project, which greatly assists 
transitional issues during the implementation phase of the process.  The “champion” 
will relate the project back to their specific interest group and through this process 
builds support for the project within their constituency (48-50). 
 
Chen’s model involves a consultative process in the development of the process and 
its implementation.  Inclusion of stakeholders in the planning and development phases 
allows incorporation of “real world” input from a range of views and specialist 
interest areas thus providing a more robust process for implementation.     
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Figure 1 – Intervention model (adapted from (47)) 
 
 
This project is not intended to provide a hard system to be followed verbatim, but 
rather explore the implementation of a system in a “real world” scenario and monitor 
the success or otherwise of the implementation.  The evaluation is intended to focus 
on why the implementation worked or not and identify other issues to be addressed to 
further encourage community nurse requests for HMR referrals. 
 
AIM 
Hypothesis:  The use of community nurses to initiate requests for HMR referral 
would facilitate uptake of HMR. 
 
The primary objectives of the project are to: 
 Develop a tailored version of the standard request for HMR referral form for 
community nurse requests for HMR referral; 
 Develop a systems based approach for community nurse HMR referral; 
 Test this form for ease of use by nurses and general practitioners; 
 Measure the degree of uptake of recommendations for HMR from community 
nurses; 
 Measure the effectiveness of the system developed; and 
 Identify barriers to uptake of HMR referrals as part of the developed system. 
 
METHOD 
Ethics 
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The project methodology was reviewed and approved (including amendments) by the 
Human Ethics Committee, School of Pharmacy, University of Queensland (Approval 
number 2004/3) and the Blue Care Research Reference Group (Research proposal 
reference number 068). 
Project site 
 
Blue Care approached BISDIV in 2003 to discuss the best method for Blue Care 
(registered) nurses to refer clients suspected of having a medication problem to their 
GP for review.  Previously, an ad hoc arrangement was used where the nurse 
concerned would telephone the doctor and express concern.  Blue Care’s preferred 
option was to devise a system whereby nurses would have a procedure to follow.  
Consequently, BISDIV sought assistance from the University of Queensland (UQ) 
and two neighbouring Divisions.   
 
Three adjacent Divisions of General Practice (Divisions) in Southern Brisbane 
involving three Blue Care centres were thus serendipitously selected as the study area: 
 Brisbane Inner South (BISDIV) (401), Bayside (403) and Brisbane South (402) 
Divisions of General Practice (Map 1); and 
 Blue Care Wynnum, Manly West and Coopers Plains centres (Map 2). 
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Map 1. Queensland Divisions of General Practice – Brisbane and surrounding 
area(51) 
 
Map 2. Blue Care centres – Brisbane city and surrounding areas (52) 
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These three Divisions combined cover a total of 1093 square kilometres and have 197 
member practices with 743 individual general practitioner (GP) members.  The Blue 
Care Centres have a combined total of 51 registered nurses (RNs) and 143 personal 
carers who visit clients in their own homes every day.  Approximately 2700 clients 
are regularly visited at varying frequencies. 
 
A comparison of the postcodes covered by each collective service is shown in Table 1 
with postcode overlap between the Divisions and Blue Care regions highlighted.. 
 
Table 1. Comparison of postcodes serviced by the Divisions and Blue Care 
Divisions of General Practice Blue Care 
Brisbane 
Inner 
South 
(BISDIV) 
Bayside 
Brisbane 
South 
Coopers Plains Wynnum 
Redland 
Bay 
4101 4072 4068 4113 4152 
4102 4073 4073 4115 
4103 4074 4074 4116 
4104 4075 4075 4117 
4105 4076 4076 4120 
4120 4077 4077 4121 4170 
4151 4078 4101 4122 
4152 4106 4102 4123  
4169 4161 4107 4103 4151 4270  
4170 4163 4108 4104 4152   
4171 4109 4105 4169   
4172 4110 4106 4170   
 4173 4111 4107 4171   
 4174 4112 4108    
 4113 4109    
 4121 4110    
 4183 4122 4111    
 4152 4112    
 
(BISDIV – italics, Bayside –  and Brisbane South – bold) 
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Study design 
 
The HMR process is well documented elsewhere (30) and was not altered for this 
project.  This project focussed on increasing the number of patients who were 
identified to their GP by a community nurse for consideration of the benefit of a 
HMR. 
 
This project was conducted in four main stages (I – IV) (Table 2). Each stage will be 
described separately. 
 
Table 2. Main stages of the project 
I Stakeholder meetings including representatives from Blue Care, Divisional 
HMR Facilitators, CEO BISDIV and Bayside Divisions, Queensland HMR 
Facilitator (Guild), GP representative and the project team convened to 
determine process issues. 
II Awareness and education of main groups involved in the project – 
community nurses, GP’s and pharmacists. 
III Patient recruitment and tracking of HMR’s through Divisions.  HMR 
facilitators in each Division provided prompts for each person involved with 
the HMR to ensure smooth progress. 
IV Focus groups conducted with each group involved in the project 
(pharmacists, GP’s and Blue Care nurses) to discuss and identify barriers in 
the project and also general barriers to HMR uptake in the community 
 
Stage I – Stakeholder meetings 
Stakeholder committee meetings comprising interested parties from the Divisions, 
Blue Care and UQ were convened to discuss the project development and 
implementation.   
 
The stakeholder committee comprised representatives from: 
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 Divisions; 
o CEO BISDIV and Bayside Division (same person); 
o HMR facilitator BISIDV and Bayside (same person); 
o HMR facilitator Brisbane South Division; 
 Blue Care; 
o DON Central Region; 
o DON South Region; 
 GP representative; 
 Guild (Queensland) HMR facilitator; 
 UQ project team; 
o Dr Lisa Nissen (academic supervisor); and 
o Greg Kyle (primary investigator and M.Clin.Pharm candidate). 
 
The role of the stakeholder committee was to provide a sounding board for the 
practicality in “real life” of the methodology and monitoring processes and also act as 
“champions for the project” within their constituencies.  Multidisciplinary 
membership was sought to represent the three professional groups involved in the 
project while also providing representation from key organisations.  The Guild 
Queensland state HMR facilitator was invited to attend to assist in outreach to 
pharmacists as she is seen as an opinion leader in HMR in Queensland. 
 
The scope and size of the project was discussed at the stakeholder meetings.  
Inclusion of the two other main community nursing service providers (St. Lukes and 
OzCare) was considered, but it was decided to limit the size of the project to Blue 
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Care alone as the Blue Care representatives believed the size of the Blue Care regions 
would provide the anticipated 50 to 100 requests for HMR referral.   
 
Stage II – Awareness and education 
The Blue Care representatives on the stakeholder committee initiated staff awareness 
of the project at regular staff meetings. The primary investigator provided education 
sessions at the three major Blue Care centres within the three Divisions of General 
Practice boundaries (Wynnum, Redland Bay, and Coopers Plains).  These sessions 
included: 
 An overview of the HMR process; 
 Ethics and Blue Care Research Reference Group approval for project; 
 Project aims; 
 Project protocols; 
 The consent process; 
o Consent form; 
o Consent must be voluntary – no coercion; 
o If the client would prefer to have someone else (trusted person eg. family, 
friend) read the form before signing, leave it with them; and 
o The client could still have a HMR if they do not want to be part of the 
study – a “normal” Request for HMR Referral” form would be completed. 
 An opportunity for questions about the project and the HMR process in general. 
 
An information pack was provided to each attendee.  This pack included a copy each 
of: 
 The existing HMR model (Appendix 1) 
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 The general project protocol flowchart (Appendix 2); 
 RN flowchart (Appendix 3); 
 The consent form (Appendix 4); 
 The project Request for HMR Referral form (Appendix 5); 
 The general Request for HMR Referral form (Appendix 6); and 
 A de-identified HMR report previously produced by the author (Appendix 7). 
 
Stage III – Patient recruitment and HMR tracking 
 
Patient recruitment was conducted between April and October 2004.  Blue Care staff 
identified patients at risk of medication misadventure or exhibiting signs of adverse 
effects.  The standard list of prompts listed on the standard Request for HMR Referral 
form (Appendix 6) was included on the project Request for HMR Referral form 
(Appendix 5) for the RNs’ reference.  Personal carers who were concerned about 
possible medication misadventure by their client(s) were requested to discuss the case 
with the registered nurse overseeing that client’s care.  The registered nurse would 
then assess the case, obtain the client’s informed consent using the consent form 
(Appendix 4) and forward a request for HMR referral form to the GP by fax if (s)he 
believed there was a potential medication issue warranting further investigation.  This 
step was included to provide consistency in the request for HMR referral process.  
Thus all requests forwarded to GP’s would be initiated by a registered nurse and have 
professional nursing review. 
 
The total number of clients approached by Blue Care RNs was not recorded since 
multiple RNs were used to recruit clients over multiple locations and there could be a 
reasonable chance of error if one or more RNs did not record every client approached. 
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The protocol developed during the Stage I stakeholder meetings was followed.  If 
follow-up was required with a GP, community pharmacy or accredited pharmacist, it 
was conducted by the HMR facilitator from the relevant Division.   Follow-up 
comprised a loop pattern at two-week intervals to maintain regular contact and 
encourage timely completion of the HMR process.  The standard HMR process was 
not altered in any way.  The only intervention made in the HMR process was the 
Divisional HMR facilitators reminding participants (GPs, community and accredited 
pharmacists) of the timelines and requesting timely progression of study HMR 
requests/referrals.  If any assistance was sought during the HMR process by 
participants (GPs, community or accredited pharmacists), it was provided by the 
Divisional HMR facilitator in their normal manner. 
 
All request for HMR referral forms were also faxed to BISDIV to provide a central 
collection point for project monitoring.  The forms for Brisbane South were then 
forwarded by fax and the forms for Bayside were taken to Bayside by the BISDIV 
HMR facilitator since BISDIV and Bayside divisions share the same person as their 
HMR facilitator.  BISDIV was chosen as the primary fax point since it was close to 
the author’s workplace and faxed forms could be collected personally to reduce 
unnecessary fax transmissions with their low, but inherent, privacy risk. 
 
The HMR facilitators from the respective Divisions monitored the progress of the 
HMR request and ultimately referral as they progressed through the standard HMR 
process.  This provided an additional benefit for the facilitators as they could use 
project cases to further their role in “evangelising” the HMR concept. 
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During May 2004, Blue Care identified the requirement for a witness signature on the 
consent form was difficult to arrange and consequently restricting patient recruitment.  
The Human Ethics Committee, School of Pharmacy, University of Queensland and 
the Blue Care Research Reference Group approved an amendment to the study 
protocol to remove the requirement for signatures to be witnessed.  The amended 
consent form is included at Appendix 8. 
 
A meeting of the two HMR facilitators and the UQ project team was convened in July 
2004 to discuss patient recruitment.  At this meeting, it was decided to broaden the 
potential recruitment pool.  Both OzCare (formerly St Vincents Nursing) and St. 
Lukes community nursing were approached by the author to gauge their interest in 
project participation.  Both organisations expressed interest in participating.  St. Lukes 
Ethics Committee reviewed and approved the study protocol.  Project timelines and 
congested training calendars, however, precluded the expansion of the study to 
include these organisations.  Difficulties were experienced arranging meetings with 
OzCare due to a dearth of mutually available times for meetings between OzCare 
senior staff and the primary investigator. 
 
Stage IV – Focus groups 
 
Focus groups were convened for each of the major groups involved in the study: 
 Blue Care nurses; 
 General practitioners; and 
 Pharmacists (both community and accredited pharmacists). 
It was anticipated that between 5 and 10 attendees would be involved in each focus 
group to represent some diversity in opinion whilst remaining a workable size. 
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The focus groups were conducted as a semi-structured discussion with a convenience 
sample of GPs, pharmacists and Blue Care RNs.    All community and accredited 
pharmacists in the three Divisions were invited to an evening meeting at the Brisbane 
South Division offices where a light supper was provided.  Two GP practice visits 
were arranged through the HMR facilitator at BISDIV and Bayside Divisions at times 
mutually convenient for the GPs, facilitator and primary investigator.  The Coopers 
Plains and Wynnum Blue Care centres were visited by appointment with the 
respective Director of Nursing.  Interviews were conducted with a group of RNs at 
each centre who were available at the time of the visit. 
 
Each profession was interviewed separately and a set of “seeding” questions was 
developed from issues evident in the literature and tailored to each group (Appendices 
9-11). 
 
All focus groups were audio-recorded and generally allowed to be a free flowing 
discussion of both HMR in general and the project model of community nurse 
requests to GPs for HMR referral.  Seeding questions (Appendices 9-11), tailored to 
each profession, were used as prompts when discussion broke down.  These quesions 
explored attitudes to the project, perceived value of community nurses requesting 
HMR referral, barriers to the uptake of the model and comments about HMR in 
general.  The general HMR questions explored attitudes to the current HMR model, 
inter-professional relationships and implementing HMR in practice. 
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All focus group recordings were transcribed verbatim, shortly after each focus group.  
Individual transcripts were repeatedly read to provide familiarity with the content.  
Open coding was completed and emergent themes identified.  Recurrent themes were 
identified across transcripts, as coding was refined.   
 
 
Each participant was provided with a Double “Gold Class” movie pass as a token of 
appreciation for his or her involvement in the focus group.   
 
With the exception of the movie passes detailed above, no remuneration was provided 
to any health professional or patient for participation in the study.  Doctors and 
pharmacists claimed their respective fees from the Health Insurance Commission for 
HMR as would normally occur outside the study. 
 
RESULTS 
Stage I – Stakeholder meetings 
 
Three stakeholder committee meetings were conducted between September 2003 and 
March 2004.  
 
A flowchart of the overall project process (Figure 2) was developed for distribution to 
all groups involved in the project.  A two-week timeframe was decided as a 
reasonable timeframe for each stage of the HMR process (GP decision, community 
pharmacy and accredited pharmacist) to ensure steady progression of the HMR whilst 
allowing sufficient time for completion of each stage.  Flowcharts were also 
developed to describe the process for each participant in the process – Blue Care 
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nurses, pharmacists, GP’s and the Divisional HMR facilitators (Appendices 3 and 12-
14 respectively).  The stakeholder committee also acted as champions for the project 
within their respective professional arena. 
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Figure 2. HMR request for referral model agreed by the stakeholder committee
No 
Referral for HMR sent 
 Pharmacy of patients choice 
 Pharmacy faxes cover sheet only to BISDIV 
(project team) – receipt of HMR referral 
Yes 
No 
Client Identification 
 Blue Care identify patient for HMR 
Completion of Request for Referral for HMR form 
 Complete form & research consent form 
 Retain original referral in patient file in home 
 Send consent form to project team 
Request for Referral sent 
 Fax to GP 
 Fax to BISDIV for project team 
GP Decides whether to refer for HMR 
 2 week decision timeframe 
 Timeframe monitored by HMR facilitators 
Feedback 
 HMR facilitator 
 Standard questions to determine 
why request for referral declined 
HMR conducted 
 2 week timeframe 
 Timeframe monitored by HMR facilitators 
Confirmation of HMR 
 BISDIV (project team) – fax signed patient consent form to 
relevant Blue Care centre as confirmation of visit 
Follow up by HMR facilitator 
 Intend to refer for HMR? 
 
HMR referred to Accredited Pharmacist 
 2 week timeframe 
 Timeframe monitored by HMR facilitators 
 
Yes 
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The stakeholder committee assisted with the design of the project Request for HMR 
Referral Form (Appendix 5).  Ready recognition as part of this study and ease of use 
by Blue Care nurses and GPs were the prime considerations.  The standard Request 
for HMR Referral Form was only slightly modified for this purpose with the logo of 
each participating group added to ensure differentiation as a project request for HMR 
referral and alterations in the “From” section.  The list of prompts to identify patients 
at high risk of medication misadventure was retained on the project Request for HMR 
Referral Form to assist Blue Care nurses.  
 
Recruitment of and gaining consent from Blue Care clients was determined by both 
the project team and stakeholder committee to be a pivotal role in this project.  It was 
recommended by the project team that consent should be obtained by the Blue Care 
nurse whom the client knew and trusted rather than by a stranger, such as a member of 
the project team.  The stakeholder committee agreed that the Blue Care nurses would 
recruit patients and gain consent.  Blue Care representatives flagged that the consent 
form could be a potential barrier to patient recruitment. 
 
Stage II – Awareness and education 
 
The education for Blue Care RNs and personal carers was conducted in mid to late 
March 2004.  The timing of the presentations was arranged to co-incide with a 
scheduled staff meeting at each centre to attract maximum attendance from Blue Care 
staff without causing undue inconvenience to rostering.  A total of 45 Registered 
nurses and personal carers attended these sessions.  Each session followed the same 
agenda and a range of questions was answered at the end of the presentation. 
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Pharmacists and GPs were advised of the project via Division newsletters, weekly 
faxes and articles included in the Pharmaceutical Society of Australia (PSA), 
Queensland Branch and Guild monthly bulletins. 
 
Stage III – Patient recruitment and HMR tracking 
 
Five requests for HMR referral were completed and sent to the GP during the seven 
months of this study.  Of these, three (60%) HMR referrals were generated by the GP 
and sent to the pharmacy.  One referral was withdrawn by the GP and two referrals 
(40%) resulted in a completed HMR.  The progress of each case through the HMR 
process is presented in Table 3.   
 
Patient 1 
Patient factors 
 
Patient 1 initially consented to a HMR and then withdrew consent when the initial 
appointment was made for GP to discuss possible HMR referral one month after the 
initial request for referral.  The GP convinced Patient 1 of the benefits of HMR and 
consent for HMR was reinstated by the patient and the referral written.  When asked 
by the GP to consider an alternative pharmacy that was approved to conduct HMR, 
the patient refused and threatened to withdraw consent if the referral was sent to 
another pharmacy. 
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Table 3.  Patient progress through the study 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Blue Care Centre Redlands Coopers Plains Wynnum Wynnum Coopers Plains 
Division of General Practice Bayside Brisbane South Bayside Bayside Brisbane South 
Date of Request for HMR Referral 16/4/04 29/4/04 1/6/04 10/8/04 26/8/04 
GP follow-up required? Yes Yes Yes Yes Yes 
Date of GP follow up #1 10/5/04 8/6/04 29/6/04 24/8/04 14/9/04 
Date of GP follow up #2 14/5/04 6/4/04 13/7/04 - 6/10/04 
Date of GP follow up #3 22/6/04 29/9/04 - - 13/10/04 
Did GP refer patient for a HMR? No No No Yes Yes 
Reason for non-referral (see below) 1 2 3 - - 
Practice visit by HMR facilitator needed? - Yes - No No 
Date referral sent to pharmacy 
14/5/04 
(withdrawn 
22/6/04) 
  26/8/04 
27/8/04 
6/10/04 
13/10/04
 
Date referral received by pharmacy    26/8/04 13/10/04 
Pharmacy follow-up required?    Yes Yes 
Number of follow-up calls required    1 3 
Pharmacy visit by HMR facilitator needed?    No Yes 
Assistance provided to find accredited pharmacist?    No No 
Date referral sent to accredited pharmacist    30/8/04 2/11/04 
Date referral received by accredited pharmacist    30/8/04 2/11/04 
Accredited pharmacist follow-up required?    No Yes 
Number of follow-up calls required    - 1 
Date HMR completed by accredited pharmacist    24/9/04 5/11/04 
Reasons for GP not referring patient for HMR: 
1. Pharmacist not approved to provide HMR.  GP and pharmacist had previously strained working relationship.  Patient adamant that no other 
pharmacy would perform HMR.  GP withdrew referral. 
2. Patient moved to another area and GP 
3. Not considered clinically necessary by GP – GP conducted medication checks.  Patient frequently in hospital (medication checked there) 
36 
Pharmacy factors 
The community pharmacy selected by the patient was not approved to conduct HMR, and the 
proprietor was on a 6-week holiday from the pharmacy.  The locum pharmacist was reticent 
to apply for approval to conduct HMR in the proprietor’s absence.  The HMR facilitator 
suggested to the GP that referral to another pharmacy could be considered to expedite the 
HMR process, but the patient refused. 
 
Upon the proprietor’s return, the HMR facilitator made contact, and the proprietor advised 
the facilitator he would pass on the referral to another pharmacy (as per the HMR protocol), 
if the GP contacted him personally.  The proprietor and the GP had a strained working 
relationship due to previous disagreements and the facilitator felt the proprietor pharmacist 
was using the HMR referral as leverage for the GP to back down over a previous matter.   
 
GP factors 
 
The GP withdrew the referral due to the unworkable nature of the relationship with the 
pharmacist and the patient’s refusal to use another pharmacy. 
 
Patient 2 
Patient factors 
Patient 2 visited many GPs and the Blue Care RN found it difficult to find one GP who felt 
(s)he knew the patient well enough to refer for a HMR.  When one of the patient’s GPs 
received the request for referral, he decided the patient would benefit from a HMR, but went 
on holidays for four weeks before the initial appointment could be made and the referral 
written.  During the time the GP was away, the patient had multiple hospital admissions.  The 
HMR facilitator visited the GP practice twice for follow-up, but before the patient could be 
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referred by the GP, the patient moved house to another area and changed GP, thus being lost 
to follow-up. 
 
Patient 3 
GP factors 
 
The divisional HMR facilitator contacted Patient 3’s GP surgery twice and was assured by 
practice staff that the GP intended to refer Patient 3 for a HMR.  On the third contact, the 
facilitator contacted the GP directly and was told that the GP did not consider the HMR to be 
clinically necessary, as the GP had already performed medication checks.  Furthermore, the 
patient was frequently seen in hospital and medication was reviewed there. 
 
Patient 4 
GP factors 
 
One GP follow-up call was required where the GP said he had sent the referral.  On further 
checking, the HMR referral had been sent to the Division office in error caused by a 
misunderstanding of the project protocol.  The referral was faxed from the Division office to 
the pharmacy and the HMR was conducted.   
 
Pharmacy factors 
 
The pharmacy did not fax the referral front page to the Division as per project protocol since 
the referral was faxed to the pharmacy via the Division office.  The HMR proceeded 
according to the standard HMR process. 
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Patient 5 
 
Pharmacy factors 
 
The first contact with the GP surgery was through practice staff as Patient 5’s GP was on 
holidays.  Practice staff were unable to find any documentation relating to Patient 5’s request 
for HMR referral.  The facilitator contacted the pharmacy specified on the request for referral 
from Blue Care and pharmacy staff were also unable to find any documentation relating to a 
HMR referral for the patient.  Contact was also made with the pharmacy’s usual accredited 
pharmacist who had not received a referral for Patient 5. 
 
When the GP practice was contacted one month later, they informed the facilitator that the 
referral for HMR for Patient 5 had been faxed to the pharmacy one day after the request for 
referral was received from Blue Care.  The facilitator again contacted the pharmacy to 
confirm receipt, but this was still denied by the pharmacy.  The GP practice was requested to 
fax the referral to the pharmacy again and complied. 
 
Two weeks later, the pharmacy was telephoned and then visited by the facilitator when they 
advised they had “misplaced” the referral.  The facilitator contacted the GP practice from the 
pharmacy and requested the referral to be sent for a third time, which was done.  The 
facilitator waited for the referral to arrive through the pharmacy’s fax and personally handed 
it to the pharmacist.  The pharmacist said the referral would be sent to the accredited 
pharmacist urgently. 
 
After a further two-week delay, the pharmacy was contacted again and said they had sent the 
referral to their usual accredited pharmacist.  The accredited pharmacist was on holidays at 
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the time, but contacted the facilitator four days later to advise the referral had not been 
received and she would contact the pharmacy for the referral for Patient 5. 
 
In early November, the pharmacy proprietor returned from an extended holiday and worked 
through the papers in his in-tray only to find three copies of the HMR referral for Patient 5.  It 
was claimed that pharmacy staff placed the faxed HMR referrals in the owner’s in-tray for 
action on his return, hence their “loss”.  The owner hand delivered the referral to the 
accredited pharmacist who interviewed the patient the next day and sent her report to the GP 
2 days later. 
 
Patient factors 
 
At the interview, the patient remembered the request for HMR referral, but said he was 
surprised the HMR was still occurring due to the time lapse since it was initially requested. 
 
Time taken at each stage of HMR process 
The time taken for the progress of each HMR through the trial process is summarized in 
Table 4.     
Table 4.  Time taken to progress through the HMR process (calendar days) 
 
Patient 
1 
Patient 
2 
Patient 
3 
Patient 
4 
Patient 
5 
Mean 
(Range) 
GP Decision 28 154 42 16 1 
48.2 
(1-154) 
CP* to AP
#
 39   4 66 
36.3 
(4-66) 
AP
#
    25 3 
14.0 
(3-25) 
* - Community Pharmacist  
#
 - Accredited Pharmacist 
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Stage IV – Focus groups 
 
The focus group meetings were all conducted in October 2004 towards the end of the study 
period.  The primary investigator attended all focus groups with Divisional HMR facilitators 
attending wherever possible.   
 
 
The focus group meetings varied in length from 29 to 105 minutes.  The final themes reflect a 
picture of attitudes towards and opinions about the HMR process and other associated issues. 
 
Blue Care nurses 
Two Blue Care focus groups were conducted – one in the Coopers Plains branch office, 
Brisbane Central Region(29 minutes, 3 RNs) and the other in the Wynnum branch office, 
Brisbane South Region (43 minutes, 6 RNs).  The Brisbane South HMR facilitator attended 
the Coopers Plains focus group.  Participants were selected by the Nurse Manager of the 
relevant office based on availability at the time of the focus group. 
 
General practitioners 
Two focus groups were conducted with general practitioners – one in Bayside (8 GPs, 40 
minutes) and the other in BISDIV (2 GPs, 46 minutes).  The GP focus groups were conducted 
at the GP practice during the normal workday at mutually convenient times.  The HMR 
facilitator from Bayside and BISDIV attended both GP meetings.  The HMR facilitator also 
selected the GP practices involved and made appointments for GP focus groups.  The 
practices selected were identified as having a favourable response to the HMR program by 
the facilitator.  This could be expected to bias the resultant themes extracted from these focus 
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groups.  The results show generally positive comments with negative comments 
predominantly relating to HMR process issues. 
 
Pharmacists 
One evening focus group (105 minutes) was conducted in the offices of the Brisbane South 
Division.  All pharmacists within the three Divisions were invited to attend via a flyer sent 
out by mail and email.  Eight pharmacists responded to the invitation and six attended the 
focus group representing a mix of 2 community and 4 accredited pharmacists.  Both 
divisional HMR facilitators attended the pharmacist focus group.  
 
Emergent themes 
Tables 5, 6 and 7 represent the main themes that emerged from the pharmacist, GP and Blue 
Care RN focus groups respectively.  Table 8 summarises the main themes across the groups. 
 
Generally, previous experience across all three professional groups was positive towards the 
HMR process.  Pharmacists found HMR to be a rewarding opportunity to talk with a patient 
outside the busy pharmacy atmosphere and that there was a chance for the pharmacist to 
really make a difference for the patient.  The GPs felt that the pharmacists were acting in a 
consultancy role in the provision of HMR and provided useful information regarding herbal 
and complementary medicines and any potential interactions with drugs.  The RNs also 
believed that HMR was a useful service and there is a great need for extension of HMR 
service in the community. 
 
All groups accepted the project system as workable.  The Blue Care nurses were more 
reticent in accepting the project model due to the amount of time involved.  When it was 
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explained that many of the time consuming parts of the project system (e.g. patient consent 
form, multiple faxes to track the HMR) were included only for research purposes, they 
accepted the “real life” version of the project system would fit their daily work schedule. 
 
The main barriers to uptake of HMR both within and outside this project were identified to be 
patient perception of the HMR, lack of time for GPs to complete the required paperwork and 
remuneration for the HMR perceived by GPs to be inadequate and therefore no incentive to 
generate many HMR.  All focus groups agreed that the patient perception of referral to a 
pharmacist for a medication review is important in increasing HMR uptake.  Marketing of the 
HMR process primarily to consumers, but also health professionals was the main suggestion 
from both the Blue Care and pharmacist focus groups to increase uptake. 
 
The current HMR model was discussed at the focus groups and some alternatives were 
suggested, but the pharmacists remained resigned to the Guild controlling the destiny of 
HMR through community pharmacy.  It was suggested that the PSA (as pharmacy’s 
professional body) should play a larger role in HMR. 
 
Blue Care nurses suggested a list of set criteria or sentinel drugs that could be used to trigger 
an automatic referral for HMR, but the GPs involved said they would be more likely to act on 
a specific clinical concern rather than a list of pre-determined criteria. 
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Table 5.  Themes from the pharmacist focus group 
Theme Issue Comments 
HMR experiences Positive Comments Improves relationship with GP 
Opportunity to talk with patient outside busy pharmacy atmosphere 
Rewarding – chance for pharmacist to make a real difference for patient 
Practice nurse can be the driver for HMR in a practice 
Patients see the benefits of talking with the pharmacist 
Negative Comments Requirement to discuss every report with GP should be changed to when the GP wants  
   clarification on the report 
Inconsistent quality of referrals – poor handwriting, lack of relevant and recent pathology 
Concern that HMR is too much work for GPs, therefore most don’t refer for HMR 
Remuneration Remuneration is pretty good considering you don’t have to supply a product or sell  
   something 
No allowance for traveling time 
No indexation of fee 
The majority of the fee should go to the pharmacist who actually does the review 
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Table 5 (continued).  Themes from the pharmacist focus group 
Theme Issue Comments 
Barriers to uptake for 
project 
Consent Some GPs don’t advise the patient that the pharmacist will be contacting them 
Most consent issues sorted out when appointment made 
One pharmacist traveled 40 minutes to patient’s house to have consent for HMR withdrawn 
Patient factors Patients are often concerned that the pharmacist will find something to reduce their   
   independence 
Patients request pharmacist not report some information to GP e.g. alcohol intake 
Project system Good idea 
RNs are not trained to look for medication related issues and therefore may miss something  
   if it is not obvious 
Use a standard criteria list for RN requests for referral “RNs don’t know what to look for     
   with medication related problems” 
RN could identify patient to pharmacist for assessment and then pharmacist refers to GP 
System improvement Inter-professional 
communication 
Receive more information from GP 
More information from a GP allows the pharmacist to provide a more useful report  
   e.g. reason for referral, recent and relevant pathology results. 
Some GPs need to accept that HMR will uncover information they are not aware of that  
   may improve patient care/outcomes 
Pharmacist sometimes contacts GP to request HMR, but only if that GP refers for HMR 
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Table 5 (continued).  Themes from the pharmacist focus group 
Theme Issue Comments 
System improvement 
(cont) 
HMR model “The timeframe is a major problem – it’s too slow” 
Accredited pharmacists already receive direct approaches for GPs for referral 
Accredited pharmacists can channel requests to community pharmacies where they are  
   contracted 
Some GP channeling to certain community pharmacies has occurred 
The Guild won’t allow HMR to go outside community pharmacy 
Community pharmacies won’t provide the dispensing history without a financial incentive 
Having patients sign off on the Claim Confirmation Form has no meaning to the patient –  
   generally explained as “just sign here to say I’ve been here today” 
The DVA provider card model for medication review service works well 
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Table 5 (continued).  Themes from the pharmacist focus group 
Theme Issue Comments 
System improvement 
(cont) 
Marketing HMR should be jointly controlled by Guild and PSA, not all to Guild 
The Guild’s only interest is to represent community pharmacy owners 
PSA involvement would improve standing of HMR in GP’s eyes 
HMR is caught in the current pharmacy/GP “turf war” on pharmacist prescribing 
Patient selection for 
HMR 
A “finders fee” may increase community RN patient identification 
Automatic request for HMR as part of Blue Care patient “enrollment” process 
Adopt the UK model, where the NHS will not pay for dose administration aid packing until  
   the patient has had a HMR 
Take RN on HMR home visit to demonstrate what occurs during HMR and have RN report  
   back to the organization on their observations may increase understanding of benefits of  
   HMR and therefore increase requests for referral 
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Table 6.  Themes from GP focus groups 
Theme Issue Comments 
HMR experiences Positive Comments Very useful to tease out issues not known to the GP 
“Pharmacists are acting as consultants – they’re making suggestions, and they’re good  
   ones” 
“All information we (GP) can get is helpful” 
9½ patients out of 10 are happy with HMR 
Useful to verify compliance and administration technique 
Pharmacists know about CAM/drug interactions – HMR are useful for this 
Negative Comments Labour intensive 
Legal liability if HMR recommendation is not followed? 
Amount of paperwork and consequently time required is a major problem 
The second consultation is theoretically only to discuss the HMR report, but the patient  
   sees it just like any other consultation and wants to discuss general issues 
Rigid HIC requirements for HMR (and other programs) are a big barrier for uptake 
Remuneration Inadequate remuneration provided for work performed 
Barrier to increased uptake 
Barriers to uptake for 
project 
Consent One (of two) local pharmacies doesn’t offer HMR – time to convince patient to use other  
   pharmacy for HMR  
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Table 6 (continued).  Themes from GP focus groups 
Theme Issue Comments 
Barriers to uptake for 
project (cont) 
Patient factors Patient can’t understand why GP can’t do HMR themselves 
Distrust GP when GP refers to pharmacist – “why are you sending me to the pharmacist?” 
Project system Confused when a Blue Care request for referral arrived – not aware a RN could request  
     HMR referral – “I didn’t know they (RN) could do this – I needed to check it was OK” 
System improvement Inter-professional 
communication 
Pharmacist should be tactful and not raise patient anxiety – if concerned, contact GP  
   directly 
If RNs detected a potentially serious problem, they should telephone GP rather than send  
   paper referral (longer delays) 
If another health professional thinks a patient could benefit from a HMR, this should be  
   communicated directly to the GP, not via the patient 
HMR model Direct referral would increase the chance of meeting the accredited pharmacist and getting  
   to know them 
Could refer direct to accredited pharmacist like any other consultant, but community  
   pharmacy(ies) would need to receive a copy of the report 
Happy to trust community pharmacy to select a good accredited pharmacist 
If the patient’s regular pharmacy doesn’t offer HMR, send them to a pharmacy that does 
Prefer the pharmacist to discuss the report to be face to face in the surgery 
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Table 6 (continued).  Themes from GP focus groups 
Theme Issue Comments 
System improvement 
(cont) 
Marketing Medical press has been generally positive towards HMR 
“I have seen the AMA opinions on HMR, but I have made my own opinions” 
Patient selection for 
HMR 
Patients on the “right drugs” who doesn’t seem to be getting better 
Referral based on a clinical concern, not a list of pre-determined criteria 
“ I’m  happy for Blue Care nurses to contact me if they think there is a problem” 
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Table 7.  Themes from Blue Care RN focus groups 
Theme Issue Comments 
HMR experiences Positive Comments Beneficial, good information provided on drugs 
Great idea and definitely of benefit to clients 
Fantastic service – huge need for it 
Most clients are on poly-pharmacy, but even we (RNs) don’t know everything they take 
Blue Care RN’s should be identifying clients to GP 
Barriers to uptake for 
project 
Consent Not appropriate to recruit demented clients 
Client felt overwhelmed with too much information during consent process 
Clients who consented were generally younger 
Patient factors Clients believed the GP knew what they were doing 
Didn’t want to be seen to go behind the GP’s back 
HMR was viewed (by client) as something the GP wouldn’t support 
Client felt they were saying the GP didn’t know what they were doing with medications 
“One client thought I (RN) was insulting her GP by  asking for a HMR” 
“Aged people have such faith and trust in their GP – they look at them like a king or God” 
Project system Amount of information required to be give for consent was time consuming 
Project was seen as a complicated process in a time poor work environment 
Simplify request for referral process (form is OK, but what to fax where was confusing) 
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Table 7 (continued).  Themes from Blue Care RN focus groups 
 
 
Theme Issue Comments 
System improvement Inter-professional 
communication 
Sending requests to GP without asking patient consent would probably increase the number  
   of requests for referral 
“If the GP suggested HMR, more clients would probably consent” 
Concern that GPs would resist direct communication from RNs 
History of slow or no response from GPs returning telephone calls, not sending referral  
   letters, etc 
“Sending HMR request to pharmacist and bypassing GP would  speed up the  
   process” 
Marketing “There should definitely be an advertising campaign for these medication reviews” 
Pharmacists should promote HMR when people collect their prescriptions 
“A sticker on medicines like the ones with extra instructions pharmacists use would be a  
   good idea” 
Patient selection for 
HMR 
Include certain criteria for triggering HMR request for referral into Blue Care’s standard  
   referral processes 
“Could we use the existing Blue Care referral form (Appendix 15).  It would reduce  
   number of forms we need” 
Select some important triggers and sentinel drugs (e.g. warfarin, benzodiazepines) 
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Table 8.  Summary of the main issues across pharmacist, GP and RN focus groups 
Theme Issue Pharmacists GPs Blue Care RNs 
HMR 
Experiences 
Positive 
comments 
Good patient benefits Obtain more information about  
   what patients do in their homes 
Fantastic service – needed by  
   most Blue Care clients 
Negative 
comments 
GP workload reducing number  
   and quality of referrals 
Very time and paperwork  
   intensive 
Nil  
Remuneration  Allowance for travel Inadequate  N/a 
Barriers to 
uptake for 
project 
Consent  Most issues sorted out when  
   appointment for visit made 
Increased time if not sending  
   patient to their regular pharmacy 
Clients overwhelmed by  
   information 
Patient factors Patients concerned about losing  
   independence 
Lack of confidence in ability of  
   GPs who refer for HMR 
Older patients see it as an insult or  
   checking up on their GP 
Project system Good idea, but are RNs trained to  
   look for medication issues? 
Unsure of HMR and project  
   models 
Time consuming and labour  
   intensive 
System 
Improvement 
Inter-
professional 
communication 
Lack of detail & reason for  
   referral in many referrals from  
   GP 
Contact GP directly and use tact  
   with patient 
History of GP communication  
   problems, but direct contact  
   would probably increase uptake 
HMR model Complex, but resigned to the fact  
   it will not change 
Direct referral would resolve  
   some time and pharmacy issues 
N/a 
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Table 8 (continued).  Summary of the main issues across pharmacist, GP and RN focus groups 
Theme Issue Pharmacists GPs Blue Care RNs 
System 
Improvement 
(cont) 
Marketing of 
HMR 
Joint Guild/PSA initiative Medical press generally positive Promote HMR directly to  
   consumers 
Patient 
selection for 
HMR 
Standardise requests and educate  
   RNs 
Based on clinical concern, not  
   standard criteria 
Standardized requests using  
   existing forms and sentinel 
drugs 
 
54 
DISCUSSION 
The results obtained from this study initially indicate a disappointing uptake rate of 
the request for HMR referral project by Blue Care nurses.  However, the results also 
suggest that the reasons behind the low number of requests for HMR referral are more 
complex than they first appear, and part of the reason for the low uptake may stem 
from the HMR process itself.  
 
Patient recruitment 
The initial number of patients for this study was anticipated to be approximately 50 to 
100.  Blue Care initially saw a huge potential for a large proportion of their clients to 
receive a HMR as most were elderly and many take multiple medications.  However, 
Blue Care representatives on the stakeholder committee and RNs at the awareness 
sessions flagged consent, and in particular the consent form as a potential barrier to 
recruitment.  The gaining of consent is an integral part of any ethical research and 
subjects should provide informed consent for research to involve their personal 
information – especially medical information.  One major complication of gaining 
consent is that it can act as a barrier to recruitment and allow selection bias for 
patients who are willing to provide consent rather than obtaining a true cross-section 
of the community under study. 
 
Barriers to recruitment 
The three main barriers to patient recruitment from the Blue Care focus groups were: 
1. The patient’s belief in their doctor; 
2. Time; and 
3. Relatively static numbers of clients in each Blue Care area. 
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Many patients were reported to believe that their doctor knew what (s)he was doing 
and they felt a request for a HMR was an insult to their doctor.  One RN said “aged 
people have such faith and trust in the GP – they think of them as a king or God”.  
The other observation from the RN focus groups was that patients who did accept the 
offer of a HMR tended to be younger.  Both these observations have been reported in 
the literature (53, 54).  Older patients (over 75 years) tended to be less likely to agree 
to participate in research in a study investigating the effectiveness of pharmacist run 
medication review clinics, and of the reasons given across all age groups, trust in the 
GP was a strong factor (54).  Another study investigating patient acceptance of 
pharmacist medication review clinics also found suspicion regarding the pharmacist 
role and the belief that the doctor could adequately perform the task (53).  These 
factors can be at least partially addressed through marketing the medication reviews 
directly to consumers to raise awareness and demonstrate the benefits that can be 
achieved. 
 
Time appears to be the foe of everything in modern life, and Blue Care RNs are no 
exception.  The demand for their services is growing with the ageing population and 
resources are not growing at the same rate.  Therefore, every minute is precious and 
this study did impose some extra burdens on the RNs, which would not occur in the 
“real world” situation.  Gaining client consent to participate and faxing forms to 
BISDIV for tracking purposes all took time and were perceived as  an inconvenience 
by RNs and potentially reduced their participation in the study.  The benefits resulting 
from the study were seen as outweighing the time  required for the  duration of the 
study, but  major concerns  were the amount of time involved and the complexity of 
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the flowchart provided (Appendix 3).  Blue Care RNs were reassured that the 
monitoring and consent issues would not remain after the study concluded and 
therefore the ongoing request for HMR referral process would be simplified. 
 
Patient pool 
Geographically, the study was limited to provide discrete RN, GP and pharmacist 
populations for the purposes of awareness and education regarding the study process.  
A major limitation with this approach is that it also limits the potential pool of 
patients who receive Blue Care services.  Initially, the Blue Care RNs approached 
their clients with enthusiasm, but after a short time, the majority of clients had been 
approached to participate in the study and the RNs could not continue to pester 
patients who declined a HMR to reconsider.  Anecdotal feedback from the Blue Care 
DoNs in the two areas involved in the study highlighted this as a major factor in 
patient recruitment.  The only new clients able to be approached for inclusion in the 
study, therefore, were new referrals to Blue Care. 
 
Awareness of HMR 
 
GPs 
Some GPs involved in the focus groups asked for clarification of the HMR model, 
thus demonstrating a degree of lack of awareness of the HMR model.  Once their 
memory was refreshed, they were able to discuss the HMR process and their 
impressions of the study protocol.  This lack of awareness is not unexpected given the 
low national uptake rate of HMR (28).   
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HMR is also only one of a range of health care initiatives involved in the Enhanced 
Primary Care program where GPs act as gatekeepers.  Other initiatives include Care 
Plans, Health Assessments, Case Conferences, Asthma 3 Plus Plan, Diabetes Annual 
Cycle of Care and the Mental Health Initiative (55).  The plethora of programs 
currently competing for GP attention and time during a consultation and the amount 
of paperwork involved in each were raised as concerns at both GP focus group 
meetings.  Consequently, HMR is not always foremost in the GP’s mind during each 
consultation, and the identification of patients who could benefit from a HMR by 
other health professionals was regarded as a good prompt for GPs. 
 
RNs 
Before becoming involved in this project, many of the RNs involved in the focus 
groups were aware of HMR, but did not know how to request a HMR for their clients.  
Many talked directly with the client’s GP or pharmacist about their concerns, but did 
not formalise these approaches.  The RNs involved in the study felt that HMR would 
be a benefit for more Blue Care clients, but awareness of HMR by GPs, Blue Care 
RNs and especially patients were obstacles to overcome. 
 
The main suggestion from Blue Care RNs regarding the lack of awareness of HMR 
was to increase marketing of HMR directly to consumers.  The RNs felt that the 
medium with the greatest impact, although expensive, would be television 
advertisements.  Other suggestions were the use of posters and brochures in GP 
surgeries (implying GP endorsement of HMR) and stickers that pharmacists could 
attach to dispensed medicines of patients taking multiple medicines, low therapeutic 
index items or having another reason to prompt a HMR.  The general opinion 
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expressed was if consumer demand increased for the service, health professionals 
would ensure they became aware of the HMR process. 
 
Pharmacists 
The general consensus among the pharmacist focus group was that increased 
marketing of HMR was required, but to GPs as well as consumers.  The pharmacists 
involved in the focus group generally believed that pharmacists were aware of HMR 
and the processes involved.  This was shown to generally be the case in the small 
sample of HMR followed to completion, albeit highlighting some major process 
issues in two pharmacies, which will be discussed below. 
 
The pharmacist focus group felt that the PSA should be more integrally involved in 
promotion of HMR, especially to GPs and other health professionals to ensure HMR 
is seen as a professional service.  At present, only the Guild is involved in HMR 
promotion and the focus group felt it could be perceived by GPs that the Guild may 
present an impression of pharmacy owners trying to boost their income.  The Guild is 
the collective body (“union”) for pharmacy owners in Australia.  Involvement of PSA 
was suggested to represent the professionalism of all pharmacists (owners and non-
owners) thereby improving the professional standing of HMR in GPs opinions. 
 
Study model 
 
Blue Care initially saw a huge potential for their clients to receive a HMR as most 
were elderly and many of their clients take multiple medications.  However, the 
stakeholder committee felt that a stranger would have a lower chance of recruitment 
of an older population into a study; hence the model using the client’s regular RN for 
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recruitment.  In hindsight, a researcher may have had an equal or increased chance of 
recruitment if more time could be allocated specifically to discussing HMR and study 
recruitment rather than as an appendage to an already busy visit by the RN.  An 
alternate model for future research could involve a parallel design with a RN 
recruitment group and a researcher recruitment group and compare the consent and 
uptake rates between the groups. 
 
Gaining patient consent 
The consent form was identified as a potential barrier to recruitment by the 
stakeholder committee and at the education sessions.  The initial version of the 
consent form (Appendix 4) included a requirement for both the Blue Care client’s and 
RN’s signatures to be witnessed.  When this was presented at the Blue Care 
awareness and education sessions, it was immediately identified as a major barrier 
since most Blue Care clients live alone and only one Blue Care RN visits.  Blue Care 
RNs made a valiant effort to recruit clients, but the witness requirement further 
restricted clients who could be approached for recruitment into the study.  A second 
version of the consent form without the requirement for signatures to be witnessed 
received ethical approved as a protocol variation, but did not appear to markedly 
improve recruitment rates.  This could have been due to the reticence of RNs to 
approach clients who had previously declined inclusion in the study when a witness 
was required on the consent form. 
 
As previously discussed, gaining of consent is an integral part of any ethical research.  
However, an argument could be put as to whether this study protocol purely involved 
audit of the existing HMR process and hence patient consent may not be required.  An 
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ethical debate could ensue as to the need for consent in this context.  Undoubtedly, 
some protocol variations would be required including coding of patients to prevent 
personal details being passed to those outside the patient’s normal care, while 
retaining the patient’s identity for the practitioners involved in the HMR process.  The 
minutiae of his debate are beyond the scope of this paper, but would be worthy of 
consideration and discussion with the relevant ethics committee if future research 
were developed using this or a similar model. 
 
HMR process 
The protocol of this study did not alter the HMR process (30) in any way; even the 
request for HMR referral was part of the already implemented HMR process.  The 
rationale for not altering the HMR process was: 
 The process was already established and funded; 
 Time involved to obtain (HMR) stakeholders endorsement of any changes to 
the process (e.g. Guild, AMA, Royal Australian College of General Practice, 
Department of Health an Ageing); 
 Ease of implementation of outcomes of this study into practice; and 
 Ability to generalise study outcomes. 
 
However, some extra steps were interleaved into the established “real world” HMR 
model to ensure the project teams awareness of patients recruited and their progress 
through the HMR process.  These were: 
 The RN faxing a copy of the request for HMR referral to BISDIV in addition 
to the GP; 
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 The GP (or staff) faxing a copy of the first page of the HMR referral to 
BISDIV when the referral was sent to the pharmacy; 
 The community pharmacy faxing a copy of the first page of the HMR referral 
to BISDIV when the referral was received by the pharmacy; and 
 The community pharmacy faxing a copy of the “Confirmation of Home 
Medicines Review consumer interview” form once the accredited pharmacist 
completed the HMR. 
 
RNs at the focus groups expressed concern at the extra requirement to fax the request 
for HMR referral to BISDIV in addition to the GP due to the time involvement.  Some 
also thought the RN flowchart provided (Appendix 3) was confusing and difficult to 
follow.  When the primary investigator explained that the fax to BISDIV was purely 
for monitoring purposes in the study and the “real world” scenario would only involve 
a fax to the GP, there was general agreement that this would be a more practical 
model. 
 
Interprofessional courtesies 
One GP in the focus groups was not aware that RNs could request a referral for HMR, 
but the general consensus was that GPs could obtain useful information from 
community based RNs (such as Blue Care) to provide better clinical management for 
patients.  Another GP commented that Blue Care could provide a valuable insight into 
how the patient managed in his or her own home thus adding hitherto unknown 
information into the clinical picture available to the GP.  GPs said they valued input 
from community nurses and other members of the health care team providing general 
etiquette regarding interprofessional communication was followed.  Many of the GPs 
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attending the focus groups told of experiences where the patient was given false 
promises about their eligibility for programs available (not limited to HMR), or the 
GP was denigrated in front of the patient.  Direct interprofessional communication 
was presented as a solution to this problem, reinforcing the value of the project model 
where the request for HMR referral form was sent directly from the RN to the GP.  In 
urgent cases, GPs said they would prefer the RN to make contact by telephone to 
ensure the problem was promptly discussed and a plan of action agreed. 
 
However, RNs in the focus groups felt their contributions to patient care were 
undervalued by GPs who were slow to return telephone calls (if returned at all) and 
provided inadequate information in referral documentation for Blue Care services.  
Pharmacists also felt some reticence on the part of GPs to impart clinical information 
about patients in HMR referrals, such as recent pathology, list of diagnoses, etc.  
Interprofessional respect and communication is an emotive arena where negative 
personal experiences and anecdotes abound.  Professional bodies may need to work 
more closely to enhance relationships and build mutual trust between health 
professionals as partners in patient well being, rather than the historical hierarchical 
model as HMR expands as a multi-disciplinary model. 
 
Potential process changes 
Pharmacists expressed concern at the skill base of RNs to reliably detect medication 
related problems.  It was not the aim of this study to expect, train or equip Blue Care 
RNs to become experts in identification of every medication related problem (actual 
or potential) their clients may be experiencing.  Neither is it the aim of the established 
request for HMR referral in the standard HMR process.  The ability for anyone 
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(health professional or not) to request a HMR based on a suspicion that a person’s 
medication(s) may be causing a problem in daily life is a strength of the HMR 
process.  It is the GP who determines potential causality and considers whether a 
HMR is warranted to further investigate the medication related problem. 
 
The pharmacist focus group suggested that the project protocol could be altered to 
have the RN identifying the patient to the community pharmacist for review.  If the 
community pharmacist felt the problem identified was medication related, then a 
request for HMR referral could be forwarded to the patient’s GP.  This suggestion has 
the community pharmacist acting as a triage point for clients identified by RNs as 
having potential medication problems.  While it may appear ideal, especially given 
the workload and other demands on GP time, it does provide an extra step (and 
potential delay) in the HMR process while the GP still remains the gatekeeper of the 
HMR process.  Given the delay times found during this study, inclusion of an extra 
step in an already slow process may only serve to add further delays and therefore 
disadvantage the patient. 
 
A complementary suggestion was made at one of the RN focus groups where it was 
suggested that RNs should be able to bypass the GP and refer directly to the 
pharmacist (community or accredited not specified) for HMR.  Changing the HMR 
process to this model would remove the major time consuming stage found in the 
HMR process during this study (GP decision – average 48 calendar days).  Given the 
growing trend towards nurse practitioners (39, 40, 56), this could be a model for 
further investigation in the future, but community nurses such as Blue Care may not 
have the patient’s full medical history available, and therefore a proportion of the 
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HMR referrals made using a nurse referral model may be inappropriate.  It could also 
be argued that a proportion of GP HMR referrals are inappropriate, but 
appropriateness of HMR referral was outside the bounds of this study. 
 
HMR model 
 
When considered from a systems viewpoint the established HMR process used in this 
study contains three main wait points with other minor wait points interspersed: 
1. The GP decision whether or not to convert a request for HMR referral from a 
RN into a HMR referral; 
 Time for the GP to see the request for HMR referral faxed from the 
RN; 
 Time and method (fax, mail, given to patient) for a referral to be sent 
to the community pharmacy; 
2. The community pharmacist actioning the HMR referral by either sending an 
accredited pharmacist staff member to conduct the review or passing the 
referral to a contracted accredited pharmacist; 
 Time for the community pharmacist to see the request for HMR 
referral sent from the GP;  
 Time and method (fax, mail, hand delivered) for the referral to be sent 
to the accredited pharmacist; 
3. The accredited pharmacist conducting the HMR; and 
 Time and method (fax, mail, given to patient) for the report to be sent 
to the community pharmacy and GP. 
 Community pharmacist preference for report delivery direct to GP 
(more efficient) or via community pharmacy (less efficient). 
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HMR timeframe 
The three main wait points monitored through this study showed delays well in excess 
of the 14 calendar days allocated as the time for each stage by the stakeholder 
committee during the initial stages of the study.  Allowing the maximum 2 weeks for 
each major stage in the HMR process, a total of 6 weeks (or 1½ months) would elapse 
between the Blue Care RN requesting HMR referral and the HMR being conducted 
and report sent back to the GP.  Using the mean times found in this study, this time 
would be 98 days, or 14 weeks (over 3 months) – more than double the time allocated 
for timely completion of a HMR in this study.  Indeed, the only group that achieved 
the target 14 day timeframe was the accredited pharmacists (14 days).  The mean 
results obtained from this study may not be able to be generalised since both the GP 
decision and community pharmacy sample sizes are only 5 and 2 respectively and 
each contain one extreme value potentially skewing the results. 
 
Notwithstanding the small sample size, these results are concerning.  Patients who are 
identified for HMR are at potential risk for medication misadventure.  Time is a 
crucial factor in assessing these patients by all members of the healthcare team to 
ensure any potential risk to the patient is minimised.  Therefore procedures should be 
instituted by GPs, community and accredited pharmacists to ensure HMR requests 
and/or referrals are dealt with in a timely manner.  Four GPs (80%) required longer 
than the allocated 14 days deciding whether or not to refer the patient for a HMR and 
three required longer than twice the allocated time (28 days or more).  These data 
indicate that GPs may not consider a request for HMR from a community RN a high 
priority in the care of a patient.  However, a significant proportion of the time taken 
may have been from the minor delays above – a delay in the GP seeing the faxed 
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request for HMR referral, or in sending the HMR referral to the community 
pharmacy. 
 
Continuity of care 
One major factor in delays in the HMR process found during this study was the lack 
of planning for continuity of patient care when health professionals took holidays.  In 
the case of Patient 1, the community pharmacy proprietor was away when the HMR 
referral arrived.  Understandably, the locum would not submit the forms for HMR 
approval of the pharmacy, but the HMR protocol, which requires an unapproved 
community pharmacy to refer the HMR to an approved pharmacy, was not followed.  
Patient 2’s GP decided to refer for a HMR, but left on 4 weeks holiday before writing 
the referral.  If the referral had been written before departure, the HMR report may 
have been waiting for the GP on his return from holidays.  Instead, the GP returned to 
find the patient had multiple hospital admissions during his absence and moved to 
another area shortly after his return.  It is not known if the hospital admissions were 
related to medication issues.  The community pharmacist proprietor for Patient 5 was 
also on holidays and staff placed all faxes that arrived in the pharmacy in his “in 
tray”.  The pharmacy manager did not appear to see the faxed HMR referrals, and 
even when the divisional HMR facilitator waited in the pharmacy, collected the HMR 
referral from the fax and handed it to the manager; it was still placed in the 
proprietor’s “in tray”! 
 
Model alterations 
Suggestions for improvements to the HMR model were sought at each focus group.  
All focus group participants felt the community pharmacist has an important role to 
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play in medication management.  The main model change suggested by the RN focus 
groups was RN initiated HMR as previously discussed.  A direct RN to pharmacist 
referral model would have the benefit of bypassing the step in the HMR process found 
to be the most time consuming – the GP decision.  The major limitation of this model 
is awareness of the patient’s medical history.  Anecdotally, most patients appear to 
have a regular (or main GP) who is aware of their medical history.  This history can 
contain valuable background information for a HMR that may not be available to the 
RN and/or community pharmacist. 
 
The pharmacist focus group was generally resigned to the fact that the HMR model 
would never move away from community pharmacy while HMR remain controlled by 
the Guild.  It was felt the model might be a little more liberal if the PSA was involved, 
but the consensus was the Guild would never (voluntarily) relinquish control of HMR.  
Most pharmacists believed that the accredited pharmacist (even if an independent 
contractor) should present him or herself as being on staff at the community pharmacy 
that received the referral – including letterhead used in reports, etc; hence reinforcing 
the community pharmacy “ownership” of the HMR process.  There was, however, a 
small degree of support for a direct referral model (where the GP refers directly to the 
accredited pharmacist), but no confidence it would ever come to fruition. 
 
GPs, however, felt a direct referral model may improve communication and 
relationships between accredited pharmacists and GPs, with the proviso that 
community pharmacists were informed of HMR outcomes.  GPs at the focus groups 
regarded HMR as a referral for a specialist opinion and see the specialist as the 
accredited pharmacist.  It was generally believed that a direct referral model would 
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increase visits to GPs by accredited pharmacists and allow discussion of GPs aims 
and needs from HMR reports.   
 
The other main difficulty GPs found with the current HMR model is the rigid HIC 
requirements that during the pre- and post-HMR consultations, only items relevant to 
the HMR should be discussed.  GPs lamented that patients do not see this distinction 
and view the visit as any other visit to the doctor where any of their medical concerns 
can be discussed.  It also needs to be remembered that many HMR recipients are 
elderly (especially the Blue Care client group) and therefore may have difficulty 
getting to the GP, hence the “omnibus” consultation.  GPs attending the focus groups 
found it difficult to limit these consultations solely to HMR matters.  Consequently, 
there was insufficient time to adequately discuss the HMR outcomes and develop a 
medication management plan.  Furthermore, HIC rules do not allow a “normal” 
consultation to be billed adjacent to a HMR consultation to accommodate patient 
needs. 
 
Remuneration 
Remuneration was a major concern for GPs with unanimous agreement from the GP 
focus groups that the current remuneration offered (full fee: $128.75, bulk billing: 
$109.45 (57)) was inadequate for the work performed by the GP in a HMR.  The 
amount of paperwork required appeared to be the largest single barrier to increased 
HMR referral from the GP perspective.  Pharmacists at the focus group generally felt 
that remuneration was adequate for the tasks performed, but would like to see the 
pharmacist fees indexed annually in a similar manner to the GP payments.  The lack 
of a travelling allowance or fee for pharmacists is an impediment to accredited 
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pharmacists travelling to visit some patients in their home.  Given this study was 
conducted in a capital city, this barrier to HMR uptake would only be magnified 
exponentially in regional, rural and remote areas.   
 
The retail background of many pharmacists was evident in the discussion regarding 
remuneration with comments such as “(the) remuneration is pretty good considering 
you don’t have to supply a product or sell something”.  It appears that pharmacy still 
has some way to travel down the cognitive services path, where remuneration for 
professional knowledge rather than for a supply or retail function, is an accepted 
mindset by pharmacists at the “grass roots” level.  The Guild and PSA may find it 
difficult to convince government, other professions and the public of pharmacy’s 
potential to deliver cognitive services if the pharmacy profession does not first accept 
this concept. 
 
Patient identification for HMR 
A major misconception with the HMR request for referral form (original) is the list of 
prompts for triggering a HMR is seen as a set of criteria that must be met.  This issue 
was raised at each focus group meeting where the “HMR criteria” were discussed.  
The HIC rules for claiming Item 900 services (HMR) state, “A medical practitioner 
must assess that a DMMR (HMR) is clinically necessary to ensure quality use of 
medicines or address patient’s needs.  Examples of risk factors known to predispose 
people to medication related adverse events are…(list as per HMR request for referral 
form)” (57).  Furthermore, the GP Guidelines produced by the Commonwealth 
Department of Health and Ageing includes “The above examples (list as per HMR 
request for referral form) serve as a guide for determining eligibility of patients for 
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DMMR, however this list is not exhaustive. For example, a patient may be eligible for 
a DMMR because of a change in circumstances, such as loss of a spouse who was 
principally responsible for medication management within the home.” (58) 
 
The Guild through the MMR facilitator scheme has been attempting to educate health 
professionals involved in HMR that the list of prompts are exactly that – suggested 
triggers which can be considered as placing the patient at increased risk of medication 
misadventure.  However, it appears that this message has not reached practitioners 
who are looking at the triggers as criteria that must be met.  The practitioner’s job is 
also made easier if the list presented is of hard and fast criteria, since it is a case of 
finding an appropriate criterion and selecting it.  HMR is more patient focused than 
this and includes “other” as a valid option whereby none of the listed triggers may 
apply to the patient, but there still may be a risk of medication misadventure and 
hence a valid reason for HMR.  More work is required in the marketing of HMR to 
health professionals to ensure that the triggers listed are not seen as a criteria list. 
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Future development 
 
A direct referral model would provide many benefits to the HMR process and 
therefore ultimately the patient.  Personality conflicts would be avoided since GPs 
would refer to accredited pharmacists with whom they had a good working 
relationship.  This would avoid the patient’s quality of care being “held to ransom” as 
occurred with Patient 1.  The wait time involved in the community pharmacist 
“processing” the HMR referral, found in this study to average 36 days, would also be 
removed.  This change would reduce the time between referral and report and avoid a 
hiatus in the HMR process as shown in the cases of Patients 1 and 5.   
Accredited pharmacists would market their services directly to GPs, thus achieving a 
twofold benefit: 
1. developing a rapport with GPs and therefore offer HMR reports tailored to the 
requirements of the individual GP or practice; and 
2. increasing GP awareness of HMR through marketing of their services to GPs. 
The current model provides no incentive for this extra “free” marketing to occur as 
accredited pharmacists receive no gain for their efforts if patients choose a community 
pharmacy where the accredited pharmacist does not work.  Another benefit would 
involve GPs being able to refer to a range of accredited pharmacists depending on 
their special interests (eg. cardiovascular, diabetes, etc).  GPs could refer patients with 
a specific problem or area of concern to an accredited pharmacist known to have an 
interest or specialist knowledge in that practice area.  Such sub-specialisation could 
provide further patient benefits. 
 
Potential disadvantages of direct referral include the potential for allegations of 
inducements provided to GPs to channel patients to a particular accredited pharmacist.  
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A direct referral system would be no different to the system currently used to refer 
patients to other medical and paramedical specialists.  Furthermore, community 
pharmacists could offer inducements for GPs to channel patients in the current model 
since there appears to be a lack of general patient awareness of HMR and 
consequently the model of using the patient’s preferred community pharmacy.   
 
Removal of the community pharmacist from the HMR process is not in the best 
interests of the patient or the HMR process.  Community pharmacist inclusion in 
HMR was also believed to be beneficial by all groups involved in this study.  If direct 
referral were to be implemented, the community pharmacist (in fact all the 
community pharmacists used by the patient) would require a copy of the report sent to 
the GP.  Currently, only the community pharmacy that receives the HMR referral 
receives a copy of the report.  Ensuring all pharmacists involved in the patients care 
are equally informed about the HMR could improve patient outcomes through quality 
use of medicine.  Future research could investigate the efficiency, patient outcomes 
and health professional and consumer acceptance of alternative HMR models 
compared with the current model.  A proposed direct referral model is at Appendix 
16. 
 
Other avenues for future research could be expansion of the catchment population to 
include HMR requests for patients on discharge from hospital, with patient 
identification by hospital ward pharmacists.  Many Blue Care clients are hospitalised 
and comparisons may be able to be drawn between uptake of requests for HMR 
between those initiated by RNs and pharmacists.   
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The current study model concentrated on three Divisions in a capital city and 
therefore does not represent a true cross-section of the Australian population and 
consequently results may not be able to be generalised outside a capital city 
population.  Further research utilising a similar model comparing city, regional, rural 
and remote populations could provide a greater insight into uptake of HMR requests 
for referral and general HMR issues across a more representative sample of the 
Australian community. 
 
Awareness and marketing of HMR were issues both raised during and arising from 
the focus groups.  Market research targeting health professionals and also consumers 
may identify further barriers to HMR uptake.  It may also provide innovative 
solutions from the relevant target populations to overcome any barriers identified. 
 
The HMR program has been in operation for three years, but remains in its infancy 
with much untapped potential.  It is hoped that future research can improve access to 
and uptake of this beneficial initiative. 
 
CONCLUSION 
Increasing the rate of HMR uptake through requests for referral from community 
nurses appears to be an easy task.  Community nurses appreciate that polypharmacy 
can contribute to increased morbidity in their client population.  However, translating 
theory into practice was more difficult than anticipated.  Client resistance to HMR 
was an unforseen barrier uncovered during this study which can be addressed through 
a consumer awareness and education program about the HMR process and its 
benefits. 
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All professions represented in this study agreed with the benefits of HMR and 
supported community RN initiated HMR requests.  Although only five RN initiated 
requests for HMR referral were received during the study period, a range of process 
issues were identified within the existing HMR model.  The overall completion of 
HMR's appeared to be unnecessarily prolonged by process issues within the GP 
practices and community pharmacies.  Patients referred for a HMR are already 
determined to be at risk of medication misadventure and prolonging the time for 
completion of the HMR process can potentially increase this risk. 
 
The main barrier to increased uptake of HMR found within the study protocol was 
obtaining patient consent for the RN to request a HMR referral from the patient’s GP.  
Focus groups identified the main barriers to increased HMR uptake in general to be: 
1. patient awareness of HMR; 
2. the amount of time taken for the GP to complete the HMR process; 
3. competing government programs; and 
4. GP remuneration. 
It is hoped that further research into HMR awareness and fine tuning of the HMR 
process can tailor the current HMR model.  The ideal outcome is a system that is 
widely recognised by health professionals and consumers to improve patient 
outcomes whilst seamlessly interleaving into everyday practice. 
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